XML 54 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating activities:      
Net loss $ (204,749,000) $ (178,840,000) $ (197,484,000)
Adjustments to reconcile net loss to net cash used for operating activities:      
Stock-based compensation expense 51,411,000 33,367,000 30,538,000
Depreciation and amortization 2,044,000 1,513,000 1,531,000
Amortization of debt discount 1,050,000 890,000 773,000
Accretion of discount on short-term investments (3,730,000) (3,412,000) (278,000)
Realized gain on available-for-sale investments (8,000) 0 0
Impairment of property and equipment 107,000 72,000  
Loss on disposal of property and equipment 62,000 29,000 39,000
Change in operating assets and liabilities:      
Accounts receivable 24,773,000 (22,778,000) (39,914,000)
Prepaid expenses and other assets (12,052,000) (7,482,000) 3,000
Inventory 14,064,000 (29,122,000) (4,768,000)
Accounts payable (14,105,000) (1,906,000) 11,955,000
Accrued clinical and manufacturing liabilities 10,144,000 (3,614,000) 13,713,000
Accrued payroll and employee liabilities 1,851,000 4,537,000 446,000
Deferred revenue     1,664,000
Other accrued liabilities 4,558,000 14,941,000 11,482,000
Net cash used for operating activities (124,580,000) (191,805,000) (170,300,000)
Investing activities:      
Purchases of short-term investments (477,035,000) (497,104,000) (121,570,000)
Maturities and sales of short-term investments 462,406,000 227,700,000 131,783,000
Purchases of property and equipment (7,154,000) (9,171,000) (2,553,000)
Proceeds from the sale of property and equipment   25,000 78,000
Net cash (used for) provided by investing activities (21,783,000) (278,550,000) 7,738,000
Financing activities:      
Net proceeds from sale of common stock and/or pre-funded warrants 162,151,000 363,128,000 306,279,000
Proceeds from purchases under the Employee Stock Purchase Plan 2,109,000 1,179,000 989,000
Proceeds from stock option exercises 22,164,000 18,301,000 11,463,000
Proceeds from warrant exercises 1,000    
Repayment of promissory note payable to related party   (25,000,000) (25,000,000)
Net cash provided by financing activities 186,425,000 357,608,000 293,731,000
Net increase (decrease) in cash and cash equivalents 40,062,000 (112,747,000) 131,169,000
Cash and cash equivalents at beginning of year 31,836,000 144,583,000 13,414,000
Cash and cash equivalents at end of year $ 71,898,000 31,836,000 144,583,000
Supplemental disclosure of cash flow information:      
Interest paid   1,183,000 $ 2,789,000
Cumulative effect of adoption of new accounting standard   $ 1,574,000